Clients

Prothena Corporation

Company Snapshot: Prothena Corporation

PRTA
Last Change Volume High Low

Company Overview

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

Client News

  1. Sep 15 2020 Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
  2. Sep 11 2020 Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
  3. Sep 11 2020 Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
  4. Sep 8 2020 Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
  5. Sep 8 2020 Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15